Introduction and Objective: A recent trial of the Omnipod® 5 AID System showed improvement in glycemic outcomes following AID initiation in a cohort of adults with insulin-treated T2D. However, limited real-world data exist on AID use and bolus behaviors in this population. This analysis evaluated real-world outcomes with Omnipod 5 use in the management of T2D.Methods: A retrospective analysis of CGM and insulin data from Omnipod 5 users with T2D in the US aged ≥18y with sufficient CGM data (≥90 days of data, ≥75% of days with ≥220 readings) was conducted for those who self-reported baseline A1C and primarily used the 110 or 120 mg/dL targets. Outcomes were stratified by baseline A1C and bolus frequency.Results: A total of 12,327 users (median age 59y; prior therapy: 44% MDI) met inclusion criteria. Users had spent a median of one year on device at the time of analysis, with 94% of time in Automated Mode. Time in range (70-180 mg/dL) and glucose management indicator by baseline A1C and bolus frequency are shown in the Figure. Among these users, time <70 mg/dL was low (median 0.26%).Conclusion: These findings from a large-scale real-world dataset of long-term (~1 year) AID use are similar to those reported in the pivotal trial of Omnipod 5 in T2D and provide evidence that people with T2D requiring insulin can consistently use AID long-term and achieve glycemic benefits even with elevated baseline A1C.
S.M. Oser: Research Support; Abbott. Other Relationship; American Diabetes Association, Association of Diabetes Care & Education Specialists. Advisory Panel; Ascensia Diabetes Care. Research Support; Dexcom, Inc., Insulet Corporation, Leona M. and Harry B. Helmsley Charitable Trust. Advisory Panel; National Committee for Quality Assurance. Consultant; Sequel Med Tech. A.L. Peters: Advisory Panel; Medscape. Consultant; Vertex Pharmaceuticals Incorporated. Research Support; Insulet Corporation, Abbott. Other Relationship; Omada Health. F.J. Pasquel: Consultant; Insulet Corporation. Research Support; Novo Nordisk, Dexcom, Inc., Ideal Medical Technologies, Tandem Diabetes Care, Inc, Insulet Corporation. Consultant; Dexcom, Inc. G. Aleppo: Consultant; Dexcom, Inc., Insulet Corporation. Research Support; Insulet Corporation, Fractyl Health, Inc., MannKind Corporation, Tandem Diabetes Care, Inc, WellDoc, EMMES, AbbVie Inc, Bayer Pharmaceuticals, Inc. E. Miller: Advisory Panel; Abbott, Abbott Diagnostics. Other Relationship; American Diabetes Association. Speaker’s Bureau; Bayer Pharmaceuticals, Inc, Boehringer-Ingelheim, Corcept Therapeutics, Eli Lilly and Company. Advisory Panel; Insulet Corporation, embecta. Speaker’s Bureau; Novo Nordisk. Research Support; Abbott. L.M. Huyett: Employee; Insulet Corporation. Stock/Shareholder; Insulet Corporation. K. Miller: Employee; Insulet Corporation. L. Conroy: Employee; Insulet Corporation. Stock/Shareholder; Insulet Corporation. J.J. Mendez: Employee; Insulet Corporation. Stock/Shareholder; Insulet Corporation. T.T. Ly: Employee; Insulet Corporation. Stock/Shareholder; Insulet Corporation.
This study was funded by Insulet Corporation.
Source link
Leave a Reply